AI assistant
Immunovant, Inc. — Director's Dealing 2023
Apr 14, 2023
31436_dirs_2023-04-14_9b62bbf8-4809-42ae-90ef-a216553b8f75.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2023-04-12
Reporting Person: Torti Frank (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-04-12 | Common Stock | A | 121916 | — | Acquired | 515274 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-04-12 | Stock Option (right to buy) | $14.7 | A | 158292 | Acquired | 2033-04-12 | Common Stock (158292.0) | Direct |
Footnotes
F1: Represents the number of shares underlying restricted stock units awards ("RSUs").
F2: The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
F3: Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date.